SML1227
Tavaborole
≥95% (HPLC), protein synthesis inhibitor, powder
别名:
1,3-Dihydro-5-fluoro-1-hydroxy-2,1-benzoxaborole, 5-Fluoro-1,3-dihydro-1-hydroxy-2,1-benzoxaborole, AN-2690, AN2690
产品名称
Tavaborole, ≥95% (HPLC)
SMILES string
B1(OCc2c1ccc(c2)F)O
InChI
1S/C7H6BFO2/c9-6-1-2-7-5(3-6)4-11-8(7)10/h1-3,10H,4H2
InChI key
LFQDNHWZDQTITF-UHFFFAOYSA-N
assay
≥95% (HPLC)
form
powder
storage condition
desiccated
color
white to beige
solubility
DMSO: 20 mg/mL, clear
storage temp.
−20°C
Quality Level
General description
Tavaborole is a boron-based pharmaceutical agent. It has broad-spectrum oxaborole antifungal activity. Due to its low molecular weight, it facilitates maximal nail plate penetration than its predecessors.
Biochem/physiol Actions
Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS).
Tavaborole (AN2690) is a potent antifungal that targets the post-transfer editing site of leucyl-tRNA synthetase (LeuRS). Tavaborole forms a covalent adduct with the 3′ adenosine of tRNA(leu) at the editing site of fungal, but not bacterial LeuRS, locking the enzyme in an inactive conformation. Tavaborole was recently approved for the treatment of onychomycosis of the toenail in adults.
存储类别
11 - Combustible Solids
wgk
WGK 3
flash_point_f
Not applicable
flash_point_c
Not applicable
法规信息
新产品
此项目有
Spotlight on tavaborole for the treatment of onychomycosis
Jinna S and Finch J
Drug design, development and therapy, 9, 6185-6185 (2015)
Tavaborole for the treatment of onychomycosis
Elewski BE and Tosti A
Expert Opinion on Pharmacotherapy, 15(10), 1439-1448 (2014)
The efficacy and safety of tavaborole, a novel, boron-based pharmaceutical agent: phase 2 studies conducted for the topical treatment of toenail onychomycosis.
Toledo-Bahena ME, et al.
J. Drugs Dermatol., 13(9), 1124-1132 (2014)
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系客户支持